Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)
Alkermes (ALKS) posted quarterly Change in Accured Expenses of $41.2 million for Q2 2026, down 22.67% year-over-year from $53.3 million in Q2 2025, and up 134.47% quarter-over-quarter from -$119.5 million in Q1 2026.
Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Change in Accured Expenses for 17 consecutive years, with $41.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 22.67% year-over-year to $41.2 million; the TTM figure through Jun 2026 stood at -$33.5 million (down 46630.56% YoY), while the FY2025 annual figure was $100.9 million, up 274.05% from the prior year.
- Change in Accured Expenses improved to $41.2 million in Q2 2026 per ALKS's latest filing, from -$119.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $73.0 million in Q4 2025 and bottomed at -$119.5 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $176833.3 across 5 years, with a median of $3.0 million in 2022.
- On a YoY basis, Change in Accured Expenses climbed as much as 1119.45% in 2024 and fell as far as 8516.2% in 2024.
- Alkermes' Change in Accured Expenses stood at $3.1 million in 2022, then sank by 34.05% to $2.1 million in 2023, then jumped by 1119.45% to $25.0 million in 2024, then jumped by 191.99% to $73.0 million in 2025, then plunged by 43.6% to $41.2 million in 2026.
- Business Quant data shows ALKS's Change in Accured Expenses at $41.2 million in Q2 2026, -$119.5 million in Q1 2026, and $73.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 41.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.19 Mn |
| Jun 30, 2026 | 41.19 Mn |
| Mar 31, 2026 | -119.47 Mn |
| Mar 31, 2026 | -119.47 Mn |
| Dec 31, 2025 | 73.03 Mn |
| Dec 31, 2025 | 73.03 Mn |
| Sep 30, 2025 | -28.25 Mn |
| Sep 30, 2025 | -28.25 Mn |
| Jun 30, 2025 | 53.26 Mn |
| Jun 30, 2025 | 53.26 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 25.01 Mn |
| Dec 31, 2024 | 25.01 Mn |
| Sep 30, 2024 | -81.05 Mn |
| Sep 30, 2024 | -81.05 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Mar 31, 2024 | -38.45 Mn |
| Mar 31, 2024 | -38.45 Mn |